BioEclipse Therapeutics (BioEclipse), a private clinical-stage biopharmaceutical company committed to developing first-in-class, curative immunooncology therapy, today announced that it has raised $7. 7 million in its Series A-1 financing round, led by Revelis Capital Group, LLC and managed by VENTURE Co Brokerage Services, LLC, with the participation of Tsingyuan Ventures, DEFTA Partners, TSVC (TEEC Angel Fund) and Plum Alley BioEclipse has raised a total of $9. $3 million to date
BioEclipse plans to use proceeds from Series A-1 funding to initiate human studies of CRX-100, BioEclipse’s patented, first-in-class, intravenous, tumor-targeted combination immunotherapy BioEclipse expects to file an Application for Investigational New Drugs (IND) with U. Oh, S Food and Drug Administration is planning to launch a phase 1b/2a clinical trial of CRX-100 in refractory solid tumor therapy in the first quarter of 2020. In the first study, the company intends to enroll patients with refractory solid tumor therapy, including ovarian cancer.
The company also announced the addition of three new board members: Mark Frohlich, MD, former Executive Vice President of Juno Therapeutics; Elona Baum, Managing Director of DEFTA Partners; and Oliver Hopkinson, Co-Founder and Managing Director of Revelis Capital Group.
“Financing the A-1 series is a watershed moment for BioEclipse,” said Pamela Contag, Ph.D. D. D. Founder and Chief Executive Officer of BioEclipse “The company is now in a prime position to advance potentially ground-breaking immunotherapy-CRX-100-that offers the potential to treat a wide range of solid and liquid tumors through a synergistic, multi-targeted mechanism of action that harnesses activated immune cells in combination with tumor killing oncolytic virus. We believe that our patented technology is unlike anything in development, and we look forward to using the Series A-1 funding to initiate the first CRX-100 clinical trial. “That’s right.
CRX-100 is designed to activate natural immune cells in patients and pair these cells with a tumor-killing agent, thereby eliminating cancer cells and creating an environment that protects the patient from recurrence of tumor growth. This first-in-class immunotherapy could provide potentially curative therapy to patients with a wide range of solid and liquid tumors, including cancers that are difficult to treat and some pediatric cancers. Preclinical studies have shown that the BioEclipse proprietary drug product can deliver approximately 1,000-fold increase in cytotoxicity compared to preclinical studies of the two components of the drug substance, both immunotherapy tested in humans, without causing serious side effects.
Dr. Dr. Contag continued: “We appreciate the support of the Revelis Capital Group, which led the Series A-1 and VENTURE rounds. Co Brokerage Services, which managed the funding Their shared vision for BioEclipse was instrumental in securing funding and will be critical to the continued success of the company. “That’s right.
New Board Members Bringing Deep Drug Industry Experience
BioEclipse continued to strengthen its Board of Directors with the addition of Dr. Frohlich, Mrs. Baum, Mr. Hopkinson’s “I am honored to welcome Mark, Elona and Oliver to our board of directors,” said Dr. Contag’s “Each of us brings a wealth of knowledge and experience to our board and understands the importance of the work we do. Our whole board looks forward to working with them “That’s right.
Mark Frohlich, MD, is an experienced biotechnological executive and medical oncologist with expertise in cell and gene drug development, oncology and immunology. He is currently a member of the Scientific Advisory Board on Oncology for Cerenis Therapeutics. Dr. Dr. Frohlich has been involved in the development of cell immunotherapy for cancer for 20 years. He was most recently Executive VP of Portfolio Strategy at Juno Therapeutics prior to the acquisition of Celgene. Previously, he served as Executive VP of R&D and Chief Medical Officer of Dendreon Corporation, where he led the clinical team responsible for the approval of the first cellular immunotherapy in the US and Europe (Provenge®). Dr. Dr. Frohlich is a graduate of Yale College with a BS in Economics and Electrical Engineering, summa cum laude, and Harvard Medical School with a PhD in Medicine. He was Chief Medical Resident and completed an in-house medical residency and then completed an oncology fellowship program at UCSF.
Elona Baum, JD, is currently Managing Director of DEFTA Partners and Head of Investment Function for its Health Technology Fund. Mrs. Baum has a career spanning more than 20 years in drug development, initially at Genentech and then at the California Institute for Regenerative Medicine (CIRM) She has played a leading role in the development of business, law and regulation In this capacity, it oversaw $1 billion of investment in regenerative medicine research and clinical programs, the creation of a $40 million pluripotent stem cell bank and the re-enforcement of intellectual property regulations governing CIRM grants. Ms at Genentech Baum managed legal issues related to the clinical trials of Raptiva and the Spanish subsidiary of the company, including serving as Secretary of the Board for Genentech Espana. Mrs. Baum currently serves as Director of the Board of Endogena Therapeutics Inc. Orig3n, Inc. She is a lawyer, serving as an outsider for Justice Arguelles of the California Supreme Court, graduated Magnum Cum Laude from the University of San Francisco Law School, and Cum Laude from the University of California, Los Angeles, with a BA in Economics.
Oliver Hopkinson is a co-founder and manager of the Revelis Capital Group, which focuses on early stage elite direct venture investment. He holds a BS in Economics from Duke University, studied at the London School of Economics and Political Science (LSE) and studied at NYU Florence.
Investors may obtain further information and risk disclosure (available exclusively to certified investors under the 506(c) exemption) by contacting the Managing Director of Investment Banking at VENTURE. Josef Ventresca, Joe@Venture C, +1 (917) 232-4112
BioEclipse Therapeutics is an emerging, clinical-stage biopharmaceutical company committed to delivering first-class, curative immunooncology therapy to cancer patients. Our focus is on currently untreated cancers where our unique multi-mechanistic combination approach could address the needs of cancer patients most of whom do not think they can be treated. BioEclipse Therapeutics is preparing to initiate phase 1b/2a clinical trials with CRX-100, a patented, first class, intravenously administered, targeted immunotherapy for solid tumors. CRX-100 is being developed to provide potentially curative treatment to patients with a wide range of tumor types, including some rare pediatric cancers. BioEclipse Therapeutics is a Johnson & Johnson Innovation resident company. JLABS, a leading life science incubator program Visit www for more information. Bioeclipse: Come on,
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/BioEclipse%20Therapeutics/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at firstname.lastname@example.org